# A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction

> **NCT07465653** · PHASE1 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 12 (estimated)

## Conditions studied

- Heart Failure With Reduced Ejection Fraction

## Interventions

- **DRUG:** HJB647 low dose
- **DRUG:** HJB647 high dose
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07465653
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-18
- **Primary completion:** 2026-09-24
- **Final completion:** 2026-09-24
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07465653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07465653, "A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07465653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*